Professor Dr Cornelis (‘Kees’) Melief has been awarded the 2022 Pedro J Romero Service to JITC Award by the Society for Immunotherapy of Cancer (SITC).
The Award recognises individuals who have made immeasurable contributions and demonstrated outstanding commitment to the Journal for Immunotherapy of Cancer (JITC) and will be presented at the SITC’s 37th Annual Meeting in Boston in November 2022.
Professor Melief, who is Chief Scientific Officer (CSO) and Founder of ISA Pharmaceuticals, will also be inducted as a Fellow of the Academy of Immuno-Oncology (FAIO), one of the SITC’s most prestigious honors.
Gerben Moolhuizen, Chief Executive Officer of ISA Pharmaceuticals, said: “We are very proud that Kees will be receiving two of SITC’s highest honors in recognition of his outstanding contributions to the field of cancer immunotherapy.
“We truly value his dedication to patients and his scientific and medical guidance within our company.”
Professor Melief is known for his translational work in devising new cancer therapies that activate the patient’s own immune system. In addition to his role at ISA Pharmaceuticals, he is Emeritus Professor of Immunology at the Leiden University Medical Center in the Netherlands.